ValiRx PLC
Company Profile
Business description
ValiRx PLC is a UK-based biopharmaceutical and life sciences company focused on advancing cutting-edge therapies in healthcare. The Company mainly engages in developing technologies and products in oncology therapeutics and diagnostics, with a focus on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It develops therapeutics across fields in oncology and has a portfolio of products in the pipeline, including GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in different stages of development.
Contact
D6 Thane Road
MediCity Nottingham
NottinghamNG90 6BH
GBRT: +44 1157840026
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
stocks
Chart of the Week: Aussie dividend yields below 10-year average
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,205.20 | 250.30 | 2.80% |
| CAC 40 | 8,205.37 | 27.48 | 0.34% |
| DAX 40 | 26,330.05 | 107.62 | -0.41% |
| Dow JONES (US) | 52,157.45 | 1,198.67 | -2.25% |
| FTSE 100 | 10,782.66 | 46.55 | -0.43% |
| HKSE | 24,796.98 | 877.48 | 3.67% |
| NASDAQ | 24,714.89 | 1,021.62 | -3.97% |
| Nikkei 225 | 61,077.90 | 1,110.73 | -1.79% |
| NZX 50 Index | 14,090.97 | 307.52 | 2.23% |
| S&P 500 | 7,464.83 | 223.79 | -2.91% |
| S&P/ASX 200 | 9,065.10 | 230.60 | 2.61% |
| SSE Composite Index | 3,689.91 | 3.74 | 0.10% |